MASS-FORMING CHRONIC PANCREATITIS: A CASE REPORT

Nguyen Dac Khanh1, Nguyen Quang Huy1, Nguyen Thi Ngoc Minh1, Vu Viet Ha1, Do Trong Ninh1
1 Sun Hospital

Main Article Content

Abstract

Background: Mass-forming pancreatitis is a distinct clinical entity in which inflammation is localized, creating a focal mass. Differentiating mass-forming pancreatitis from pancreatic cancer remains one of the most significant challenges for radiologists. Due to its tumor-like presentation, patients are frequently misdiagnosed with malignancy.


Case report: We present a case of a 70-year-old female with a history of breast cancer who was admitted with obstructive jaundice. Ultrasound, CT scanner and magnetic resonance imaging revealed a mass in the pancreatic head associated with enlargement of the pancreatic body and tail. Laboratory findings showed elevated bilirubin; however, tumor markers (CEA, CA 19-9) and pancreatic enzymes (amylase, lipase) were within normal limits. Notably, initial blood work showed leukocytosis with an increased neutrophil percentage. Following biliary drainage to relieve the obstruction, subsequent tests revealed a persistent elevation in both the absolute white blood cell count and the eosinophil count (percentage and absolute), along with markedly high serum IgE and a borderline increase in IgG4 levels. Based on these findings, the patient was diagnosed with a suspected case of Type 1 autoimmune pancreatitis, characterized by concurrent peripheral eosinophilia and elevated serum IgE levels, which showed a favorable response to Corticosteroid therapy.


Conclusion: Type 1 autoimmune pancreatitis with eosinophilia and hyper-IgE can manifest as a mass-forming pancreatic lesion, mimicking pancreatic malignancy. Recognizing this specific clinical phenotype is crucial in clinical practice to ensure an accurate diagnosis and prevent unnecessary surgical interventions.

Article Details

References

[1] Shimosegawa T, Chari S.T, Frulloni L et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas, 2011, 40 (3): 352-358. doi: 10.1097/MPA.0b013e3182142fd2
[2] Yarandi S.S, Runge T, Wang L et al. Increased incidence of benign pancreatic pathology following pancreaticoduodenectomy for presumed malignancy over 10 years despite increased use of endoscopic ultrasound. Diagn Ther Endosc, 2014, 2014: 701535. doi: 10.1155/2014/701535
[3] D’Onofrio M, Zamboni G, Tognolini A et al. Mass-forming pancreatitis: value of contrast-enhanced ultrasonography. World J Gastroenterol, 2006, 12 (26): 4181-4184. doi: 10.3748/wjg.v12.i26.4181
[4] Gallo C, Dispinzieri G, Zucchini N, Invernizzi P, Massironi S. Autoimmune pancreatitis: cornerstones and future perspectives. World J Gastroenterol, 2024, 30 (8): 817-832. doi: 10.3748/wjg.v30.i8.817
[5] Kuruma S, Kamisawa T, Tabata T et al. Allergen-specific IgE antibody serologic assays in patients with autoimmune pancreatitis. Intern Med, 2014, 53 (6): 541-543. doi: 10.2169/internalmedicine.53.0963
[6] Michailidou D, Schwartz D.M, Mustelin T, Hughes G.C. Allergic aspects of IgG4-related disease: implications for pathogenesis and therapy. Front Immunol, 2021, 12: 693192. doi: 10.3389/fimmu.2021.693192.